RMSS Immersive Virtual Training Course

Welcome & Introduction, Anne Sailer, MD, Yale University, Julia D'Souza, MD, Geisinger Health System

Liver-Directed Therapy: How to work up a liver tumor patient, Michael Soulen, MD, FSIR, FCIRSE, University of Pennsylvania

• Review of guidelines/staging/role of IR in managing primary HCC
• Review of guidelines/role of IR in managing metastatic colorectal cancer
• Basics of Liver Ablation
• Basics of Liver Embolization (Bland, Chemoembolization, and Y90)
• Basic considerations when choosing between therapies

IO Literature Review TACE: Data and Methodologies Surrounding TACE for HCC and Metastases: Khashayar Farsad, MD, PhD, OHSU

• Data supporting TACE for HCC and metastases, including need-to-know trials for TACE for tumor board
• Role of various embolics

IO Literature Review Y-90: Data and Methodologies Surrounding TARE for HCC and Metastases: Riad Salem, MD, MBA, Northwestern Feinberg School of Medicine

• Data supporting TARE for HCC and metastases, including need-to-know trials for TARE for tumor board
• Y90 How To: review of patient selection, Y90 dosing, and follow-up
• Timing with chemotherapy in metastatic disease patients

Advanced Course in TARE: Dosimetry for Senior Residents: Tyler Sandow, MD, Ochsner Health

• Dosimetry methodologies: BSA, MIRD, Partition, Voxel-based
• Considerations for individual tumors and individual patient constraints
• What to assess for on planning arteriography and mapping MAA SPECT
• Programs or adjuncts (ex: 3D lab partitioning) that you use to calculate your dosimetry

Ablation Literature Review: Data and Methodologies Surrounding Ablation for HCC and Metastases: Meaghan Dendy-Case, MD, MA, Vanderbilt University

• Data supporting established role for ablation for HCC and metastases, including need-to-know trials for ablation for tumor board
• Margins and proof of margins (ablation confirmation) and techniques
• TACE-ablation

HCC in the Setting of Immunotherapy: Richard Finn, MD, UCLA

• Major combination therapy trials
• Timing of LDT and immunotherapy
• Gaps in data/ongoing trials: what would be helpful for the future

MSK Interventions: Spine: Alan A. Sag, MD, University of Miami

• Overview of IR’s role in pain management
• Data supporting kyphopasty and ablation for compression fractures
• RFA versus cryoablation for metastasis ablation
• Additional spinal interventions (brief): BVNA, spinal stimulator implantation

MSK Interventions: Pelvis + Additional Pain Interventions: Matthew J. Scheidt, MD, FSIR, Medical College of Wisconsin

• Acetabular reconstruction and sacroplasty
• Structural considerations
• Pain versus function in masses involving nerves
• Pain from tumors beyond the axial skeleton

Renal Tumors: Initial Patient Workup: Andrew J. Gunn, MD, University of Kentucky

• Renal tumor treatment based on size and classification systems. Guidelines and data for RCC ablation
• Patient and tumor selection
• How To: Procedural approach and considerations

Advanced Considerations and Techniques for Renal Interventions: Ron Arellano, MD, FSIR, FACR, FCIRSE, Massachusetts General Hospital

• Hard-to-ablate lesions: Considerations, techniques, and case-based review
• Combined embolization and ablation

Lung Tumors: Initial Patient Workup: Erica Alexander, MD, MSKCC

• Basics of lung IO Procedures from diagnosis (biopsy) to treatment
• MWA vs Cryo vs RFA vs newer ablation modalities – what to choose and when

Advanced Considerations in Lung Interventions: Robert Suh, MD, UCLA

• Advanced maneuvers: Approaches and techniques for tough-to-ablate tumors
• Managing complications: persistent pneumothoraces and bronchopleural fistulae